Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Ibrutinib + Obinutuzumab vs Ibrutinib + Obinutuzumab in Untreated Younger CLL Patients
NCT03701282Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2019
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of venetoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 10 years. Started Feb 2019; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03701282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03701282.